Organogenesis Holdings Inc. (ORGO)

↓ Download CSV

CIK 0001661181 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

In fiscal 2025, Organogenesis Holdings Inc. reported revenue of $564.17M, up 17.0% from the prior year. The company was profitable, with a net margin of 6.6%. It held $598.73M in total assets against $164.81M in total liabilities.

Key ratios (FY2025)

7.9%
Operating margin
6.6%
Net margin
12.3%
Return on equity
+17.0%
Revenue growth (YoY)
Metric (FY)2025202420232022202120202019201820172016
Revenue$564.17M$482.04M$433.14M$450.89M$467.36M$338.30M$260.98M$193.45M$198.51M$138.73M
Cost of Revenue$115.74M$106.48M$105.02M$114.20M$87.32M$75.95M$68.81M$61.22M$48.20M
Gross Profit$366.30M$326.66M$345.87M$353.16M$250.98M$185.03M$124.64M$137.29M$90.53M
Operating Income$44.69M-$1.28M$12.53M$22.30M$72.22M$26.70M-$29.85M-$51.56M-$5.49M-$8.78M
Net Income$37.03M$861.0K$4.95M$15.53M$94.20M$17.23M-$38.71M-$64.83M-$8.39M-$16.99M
EPS (Diluted)$0.15$-0.01$0.04$0.12$0.70$0.15$-0.42$-0.94
Total Assets$598.73M$497.89M$460.02M$449.36M$443.26M$290.22M$220.69M$163.68M$148.72M$311.44M
Total Liabilities$164.81M$112.57M$181.36M$183.69M$201.92M$148.41M$165.10M$116.64M$157.28M$11.33M
Shareholders' Equity$300.13M$262.90M$278.66M$265.67M$241.34M$141.81M$52.02M$39.94M-$15.32M-$15.98M
Cash & Equivalents$93.68M$135.57M$103.84M$102.48M$113.93M$84.39M
Operating Cash Flow-$10.31M$14.21M$30.92M$24.86M$61.98M$5.47M-$33.53M-$60.63M-$3.49M-$4.87M
Capital Expenditures$14.15M$10.03M$24.36M$33.90M$31.22M$17.68M$5.98M$1.86M$2.43M$1.36M
Shares Outstanding126.95M125.73M131.32M130.92M128.68M127.73M104.87M91.26M66.98M